11/4/2026

speaker
Sylvie
Conference Call Operator

Good afternoon and welcome to the Progeny, Inc. Third Quarter Earnings Conference Call. At this time, all participant lines are in listen-only mode, and we will open the floor for your questions after the presentation. If you wish to join the queue to ask a question at any time, please press star 1. Should you wish to remove yourself from the queue, press star 2. It is now my pleasure to turn the floor over to your host, James Hart. The floor is yours.

speaker
James Hart
Vice President, Investor Relations

Thank you, Sylvie, and good afternoon, everyone. Welcome to our third quarter conference call. With me today are Peter Anevski, CEO of Progeny, and Mark Livingston, CFO. We will begin with some prepared remarks before we open the call for your questions. Before we begin, I'd like to remind you that our comments and responses to your questions today reflect management's views as of today only and will include statements related to our financial outlook for both the fourth quarter and full year 2026, and the assumptions and drivers underlying such guidance, the demand for our solutions, our expectations for our selling season for 2027 launches, anticipated employment levels of our clients and the industries that we serve, the timing of client decisions, our expected utilization rates and mix, the potential benefits of our solution, our ability to acquire new clients and retain and upsell existing clients, our market opportunity, and our business strategy, plans, goals, and expectations concerning our market position, future operations, and other financial and operating information, which are forward-looking statements under the federal securities law. Actual results may differ materially from those contained in or implied by these forward-looking statements due to risks and uncertainties associated with our business, as well as other important factors. For a discussion of the material risks, uncertainties, assumptions, and other important factors that could impact our actual results Please refer to our SEC filings and today's press release, both of which can be found on our investor relations website. Any forward-looking statements that we make on this call are based on assumptions as of today, and we undertake no obligation to update these statements as a result of new information or future events. During the call, we will also refer to non-GAAP financial measures, such as adjusted EBITDA. More information about these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, are available in the press release, which is available at investors.progeny.com. I would now like to turn the call over to Pete.

speaker
Pete Anevski
Chief Executive Officer

Thanks, Jamie, and thanks, everyone, for joining us this afternoon. I'm pleased to report that Progeny had a strong quarter, resulting in record revenue and profitability for the third quarter, as well as the continued generation of significant cash flow, which we're using both to invest in the business for future growth and return value to our shareholders through meaningful share repurchase activity. As the fourth quarter begins, member engagement remains healthy. Given that, as well as our strong performance over the first nine months of the year, we're pleased to be in a position to raise the midpoint of our full year guidance. Mark will take you through those details shortly, as well as the highlights from the quarter. I'll spend my time this afternoon walking you through the results of our most recent selling and renewal season as those are the areas that contribute the most to our longer-term growth trajectory. We're exceptionally pleased with our results this selling season, which yielded a record 1.3 million new covered lives and over 85 new clients. These outstanding results begin with the continued macro demand by plan sponsors for this critical benefit, and driven by across the board execution from all of our go-to-market strategies and teams. This year's season, once again, highlights our meaningfully differentiated solutions from alternatives in the market. Let me spend the rest of my time today unpacking this headline. We enter every selling season with multiple priorities, acquiring new logos and lives, retaining our existing base, and deepening our relationships with existing accounts through the expansion of their services with projects. Across all three aspects of this year's season, we once again achieved or exceeded our targets. Starting with new client acquisition, throughout the year, we've discussed the favorable activity we were seeing in new client acquisition. We attribute this momentum to a few areas that we see continuing beyond this selling season. The first is that family building and women's health are a key priority for employers. We're addressing very real, very prevalent medical needs, ones that can be costly and even harmful to the workforce when they're not well managed. In fact, this has been featured by a number of analysts in recent research reports as market surveys and key opinion leader calls continue to validate that these programs are top of mind for HR leaders. It's also no secret that employers and members are dealing with some of the highest costs and trends in decades. Employers are demanding more from their partners, looking to drive costs down and control trends. all while expecting the highest quality outcomes and member experience. Companies continue to employ rigorous processes to determine the right solutions that fit this criteria and Progeny's ability to demonstrate its proficiency in delivering on these promises backed by a proven track record across all key areas differentiated our solution versus other competitors for these discerning buyers again and again. The emphasis on value, cost control, outcomes, and member experience is what drove this momentum throughout the season. From its earliest stages while the pipeline built through the summer and fall and even extended into the season's latest stages as reflected by the incremental 100,000 lives just since the last update of our expectations that we put out a month ago. The activity this season wasn't isolated to one geography, one industry, or one type of client. Rather, our wins this year represent yet another diverse cross-section of the economy, no different than what we've seen for many years now. Our newest clients include several of the most prestigious universities in the country, another of the MAG7 technology leaders, one of the largest banks in the U.S., and the nation's or just health benefit fund for public employees. The cohort is also broadly distributed by client size where the newest logos are contributing anywhere from 1,000 to well in excess of 100,000 lives, further highlighting the universal relevance and appeal of our services. Accordingly, we're entering 2027 with our most diverse client base ever with no one area of the economy and no single client making an outsized contribution to our buck. This newest cohort is also launching with the typical coverage levels that we've seen for many years now, with an average of two to three smart cycles. And amongst these new clients, we've achieved a near 100% attach rate for our pharmacy program, emphasizing once again the value and differentiation of progeny Rx to both the patient and the plan sponsor when measured against the alternatives. Regarding market alternatives, while the competitive environment remains active, we continue to see signs of some rationalization occurring in the market. The models that perhaps may not be profitable, that perhaps may not be operating at scale or haven't been successful at controlling cost trend, We've seen one of those companies exit altogether a year ago and we're now seeing another significantly pairing back. These are signs of a well-functioning market where capital flows to the models that have been proven to work, like ours, and our results this season clearly speak to the robust appetite for a proven solution from employers. To be clear, While takeaways from competitors provided a nice contribution to our results, this was not an outsized driver to this season's success. Instead, this season reflects the confluence of several of our strategies, including the furtherance of our channel partners, particularly our relationship with Cigna as our national partner, as well as the largest regional plans, the disciplined management of our go-to-market strategies and resource allocation, and our ability to successfully respond to where the market is by continuing to invest in our solution so that there is no question on the value we deliver when we discuss our solution in detail with these prospects. As expected and consistent with our prior commitments, Progeny Select, our newest offering in the fully insured market, was an immaterial contributor to this season's results. As this is our first year with that program, Our focus has been on building the relationships and the infrastructure that will allow us to meaningfully scale it over time. And based on our progress in both areas this year, as well as the feedback we're hearing in the market, we continue to expect select will become a key part of our longer-term growth. Turning to the other areas of focus in the selling season, retention and expansions. As highlighted earlier this year, We had de-risked our retention by securing early decisions with the largest accounts in a renewal year. And we saw this favorable activity continue over the balance of the season, leading to yet another year of near 100% retention of the existing base. In addition, approximately 20% of the base has chosen to add to their solution in some way for 2027. This includes those clients who have decided to consolidate with Progeny and the other aspects of women's health services that competitors were previously addressing for them. As we start to look into next year's season, we believe we're exceptionally well positioned to extend the momentum we experienced this year in the 2027. We're exiting the year with our strongest ever setup for the upcoming season ahead, both in terms of our number of opportunities as well as the overall size and quality of the pipeline. indicating that this year's market momentum is contributing not only to this year's selling season, but to next year's as well. In conclusion, on top of everything else, we're excited and entering the upcoming 2027 season with our strongest sales momentum ever. Let me now turn the call over to Mark to review the results in more detail.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API